TSTickerStarGet alerts

Daré Bioscience Reports Q3 2026 Financial Results

Daré Bioscience reported Q3 2026 revenue of approximately $48,000 compared to approximately $2,300 in Q3 2025, with the increase attributable to research and development services revenue under Gates Foundation agreements and initial Flora Sync LF5 sales that began in July 2026. Net loss improved to approximately $3.2 million from approximately $3.6 million in the prior year period, while EPS improved to $(0.18) from $(0.28). The company expects to begin recording revenue from DARE to PLAY Sildenafil Cream in Q4...

Share this story

Key takeaways

  • Revenue increased to approximately $48,000 in Q3 2026 from approximately $2,300 in Q3 2025, driven by Gates Foundation research services revenue and initial Flora Sync LF5 sales

  • Net loss improved to approximately $3.2 million from approximately $3.6 million year-over-year; EPS improved to $(0.18) from $(0.28)

  • Selling, general and administrative expenses remained relatively flat at approximately $2.6 million versus approximately $2.5 million in Q3 2025

  • Research and development expenses decreased to approximately $0.3 million from approximately $1.2 million, primarily due to decreased costs for Sildenafil Cream, DARE-LARC1, and Ovaprene programs

  • Cash position was approximately $11.5 million with working capital of approximately $3.2 million as of September 30, 2026

  • DARE to PLAY Sildenafil Cream prescription dispensing activities commenced in November 2026 across 48 states and Washington, D.C.

  • Flora Sync LF5 has generated orders from 27 states with a 4.9-star consumer review rating and first provider office reorder

Key metrics

Total revenueQ3 2026
$48,000+$45,728
Research and development services and other revenueQ3 2026
$47,628
Net lossQ3 2026
$3.2 million$0.4 million improvement
Loss per common share - basic and dilutedQ3 2026
$(0.18)$0.10 improvement
Selling, general and administrative expensesQ3 2026
$2.6 million+$0.1 million
Research and development expensesQ3 2026
$0.3 million-$0.9 million
Cash and cash equivalentsSeptember 30, 2026
$11.5 million
Working capitalSeptember 30, 2026
$3.2 million

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow DARE in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert